tbuckley/cabot-search huggingface dataset:
Incorrect Location
Authors: Allyn Nakashima, Rosemarie Horsley, Robert Frey, Patricia Sweeney, J Weber, Patricia Fleming
Journal: JAMA (1999)

counseling and testing data system was begun, and 1 (Florida) began HIV reporting very recently and not enough time has elapsed to have adequate data for analysis.The year-to-year median percentage changes in total number of HIV tests during 1992 through 1996 for areas with and without HIV reporting were similar in magnitude and trend. 2 Although we showed no large declines in testing among MSM and other risk groups after HIV reporting, we agree with Arago ´n and Myers and Dr Woods and colleagues that trends in some subgroups-for example, in a small number of MSM concerned with reporting issues-could be hidden within the larger community of MSM.Because there will always be individuals concerned about these issues, we emphasized the importance of making anonymous testing available to promote knowledge of HIV status among at-risk people.The approval by the US Food and Drug Administration of home sample collection tests for HIV expands the availability of anonymous testing in all areas. 3oods et al also state that, except for New Jersey, we included only low-prevalence states.This is incorrect.Louisiana (acquired immunodeficiency syndrome [AIDS] rate of 33.7 per 100 000 in 1997) and Tennessee (25.1 per 100 000) have high AIDS incidence, comparable with their own state of California (29.8 per 100 000) 1 and are considered moderateprevalence states.Dr Solomon and colleagues are concerned that the study design was ecological and subject to the fallacy inherent in such studies, ie, that ecological correlations cannot be validly substituted for individual correlations.However, to demonstrate the impact of a policy change on a large population, ecological methods may be the most practical design.In an individual-level study, each individual's awareness of the change in policy would be determined.On a population basis, this would be a difficult study to conduct, especially if attitudes of high-risk persons were to be assessed.Although our study cannot distinguish between people who were aware ("exposed") and unaware ("not exposed") of the change in reporting policy, the important fact remains that no large changes in testing behavior were observed in the population.Our results are supported by a recent study of more than 2500 people in high-risk groups (MSM, IDUs, and attendees of sexually transmitted disease clinics) in 9 states. 4In this study, more than 60% of participants were unaware of their state's HIV reporting policy and, of those avoiding testing, only 2% stated that reporting was a main factor for not being tested. 4urthermore,
27-Hydroxycholesterol impairs neuronal glucose uptake through an IRAP/GLUT4 system dysregulation
Authors: Muhammad-Al-Mustafa Ismail, Laura Mateos, Silvia Maioli, Paula Merino-Serrais, Zeina Ali, Maria Lodeiro, Eric Westman, Eran Leitersdorf, Balázs Gulyás, Lars Olof-Wahlund, Bengt Winblad, Irina Savitcheva, Ingemar Björkhem, Angel Cedazo-Mínguez
Journal: The Journal of Experimental Medicine (2017)

Hypercholesterolemia is associated with cognitively deteriorated states. Here, we show that excess 27-hydroxycholesterol (27-OH), a cholesterol metabolite passing from the circulation into the brain, reduced in vivo brain glucose uptake, GLUT4 expression, and spatial memory. Furthermore, patients exhibiting higher 27-OH levels had reduced 18F-fluorodeoxyglucose uptake. This interplay between 27-OH and glucose uptake revealed the engagement of the insulin-regulated aminopeptidase (IRAP). 27-OH increased the levels and activity of IRAP, countered the IRAP antagonist angiotensin IV (AngIV)–mediated glucose uptake, and enhanced the levels of the AngIV-degrading enzyme aminopeptidase N (AP-N). These effects were mediated by liver X receptors. Our results reveal a molecular link between cholesterol, brain glucose, and the brain renin-angiotensin system, all of which are affected in some neurodegenerative diseases. Thus, reducing 27-OH levels or inhibiting AP-N maybe a useful strategy in the prevention of the altered glucose metabolism and memory decline in these disorders.
NK Cell Recovery and Costimulatory Molecule Profiles after Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM) Patients
Authors: Myo Htut, Ghislaine Gallez-Hawkins, Joycelynne Palmer, Laetitia Jeannet, Leanne Goldstein, Andy Dagis, Ricardo Spielberger, Pablo Miguel Parker, Len Farol, Firoozeh Sahebi, Chatchada Karanes, Stephen J. Forman, Amrita Krishnan, John A. Zaia
Journal: Blood (2014)
Temporal Acquisition of FLT3-ITD or RAS Mutation at Transformation to AML from MDS: Clinical Implications
Authors: Talha Badar, Philip A Thompson, Binsah George, Naval Daver, Gautam Borthakur, Jorge E. Cortes, Marina Konopleva, Tapan M. Kadia, Zach Bohannan, Sherry Pierce, Elias Jabbour, Farhad Ravandi, Hagop M. Kantarjian, Keyur P. Patel, Raja Luthra, Victoria Sukholutsky, Guillermo Garcia Manero
Journal: Blood (2014)
PDCT-04. NEUROLOGICAL OUTCOME IN DELAYED DIAGNOSIS OF SPINAL CORD, BRAINSTEM, AND CEREBELLAR LOW-GRADE GLIOMAS
Authors: Zsila Sadighi, Elizabeth Curtis, Jennifer Zabrowski, Catherine Billups, Raja Khan, Ibrahim Qaddoumi
Journal: Neuro-Oncology (2016)

We present neurological outcomes in pediatric spinal cord, brainstem, and cerebellar low-grade gliomas (LGG) with delayed diagnosis, not previously described. We retrospectively examined neurological outcome in pediatric LGG with delayed diagnosis from 1995-2015 in 103 patients (55 posterior fossa/cerebellum, 33 brainstem, and 15 spinal cord). Neurological severity was measured at diagnosis and last follow-up using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 for 40 deficits, Modified Rankin Scale (MRS), and Karnofsky Performance Score (KPS). Pre-diagnosis interval (PSI) 0-3 months, 3-6 months, and > 6 months of symptoms to first radiological diagnosis determined extent of delay. The Kruskal-Wallis test compared severity by PSI group. We found 103 patients (52% male), median age at cancer diagnosis 7.1 (0.1-17.5) years and median time to last follow-up 11 years (<1 month-20.7 years). Median MRS for all patients was 2.0 at baseline and 2.0 at follow-up. Median KPS for all patients was 90 at baseline and 80 at follow-up. In PSI <6 months, MRS declined from 1.5 to 2.0 score between visits and KPS declined from 90 to 80. In PSI ≥ 6 months, MRS and KPS were unchanged (2.0, 90, respectively). Most common deficits at first exam were ataxia (37.9%), gait disturbance (36.9%), and dysmetria (32%); versus last exam, gait disturbance (39.8%), cognitive disturbance (36.9%), and ataxia (35.9%). Over time dysesthesia and paresthesia worsened in 11.4% patients with PSI ≥6 months compared to 1.7% patients with PSI < 6 months (p=0.06 each). Urinary retention worsened in 7.7% patients with PSI ≥6 months compared to 0% patients with PSI < 6 months (p=0.05). Delayed diagnosis of children with low-grade gliomas in spinal cord, brainstem, and posterior fossa impacts some neurological function over time. Dysesthesia, paresthesia, and urinary retention are worse in patients diagnosed ≥6 months.
Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) – Primary endpoint and subgroup analysis of the CEBIFOX trial
Authors: S. Kasper, J. Meiler, H. Knipp, T. Höhler, P. Reimer, H.T. Steinmetz, W. Berger, G. Linden, S. Ting, P. Markus, A. Paul, A. Dechêne, B. Schumacher, K. Kostbade, K. Worm, K.W. Schmid, T. Herold, M. Schuler, T. Trarbach
Journal: Annals of Oncology (2016)
The KIT D816V Allele Burden in Systemic Mastocytosis Is Strongly Associated with Disease Subtype.
Authors: Juliana Schwaab, Philipp Erben, Hans-Peter Horny, Martina Teichmann, Georgia Metzgeroth, Thomas Ernst, Karl Sotlar, Martin C Mueller, Alexander Marx, Karin Hartmann, Andreas Hochhaus, Nicholas C.P. Cross, Wolf Karsten Hofmann, Andreas Reiter
Journal: Blood (2012)
nab-paclitaxel (nab-P) + carboplatin (C) induction therapy in patients (Pts) with squamous (SCC) NSCLC: Interim quality of life (QoL) outcomes from the phase 3 ABOUND.sqm study
Authors: M. Thomas, S. Ponce Aix, A. Ko, R. Jotte, T.J. Ong, R. Page, M. Socinski, N. Trunova, V. Villaflor, D.R. Spigel
Journal: Annals of Oncology (2016)
Local accrual pattern of a breast cancer adjuvant chemotherapy clinical trial
Authors: A. Chan, J. C. Yau, S. Huan, D. Vergidis, K. Cranston, C. Falkson, H. Dhaliwal
Journal: Journal of Clinical Oncology (2004)

878 Background: Less than 5% of new cancer patients participate in clinical trials. The objective of this study was to evaluate accrual to a clinical trial of breast cancer adjuvant chemotherapy at a regional cancer centre. Methods: A retrospective review of patients treated for primary breast cancer between June 2001 and June 2003 was conducted. Results: 165 charts were reviewed. 62 patients received adjuvant chemotherapy. Of these, 42 (68%) fit the age criteria for the clinical trial. 15 were ineligible due to tumor characteristics. Of the 27 patients who were eligible for the trial based on age and tumor characteristics, 12 (44%) could not be treated on clinical trial because they lived in a peripheral community. Of the 15 remaining patients who were eligible for treatment on clinical trial at the cancer center, 7 (47%) were actually entered in the trial. Patient's fear of potential toxicity was the primary reason for not participating in the clinical trial. Conclusions: At our institution, living in a peripheral community was a leading reason for ineligibilty for a clinical trial of adjuvant chemotherapy of breast cancer. Accrual to this specific trial was nearly half of all patients who were eligible based on age, tumor characteristics, and location. No significant financial relationships to disclose.
Estimating the Chances of Older AML Patients to Achieve a Complete Remission Upon Intensive Induction Chemotherapy - An AMLCG and SAL Study
Authors: Utz O Krug, Christian Rohde, Achim Heinecke, Maria Cristina Sauerland, Anja Koschmieder, Christoph Röllig, Markus Schaich, Christian Thiede, Michael Kramer, Jan Braess, Karsten Spiekermann, Torsten Haferlach, Claudia Haferlach, Gerhard Ehninger, Bernhard Josef Woermann, Wolfgang E. Berdel, Wolfgang Hiddemann, Thomas Buchner, Carsten Müller-Tidow
Journal: Blood (2010)
STMC-15. INNATE IMMUNE SIGNALING VIA TLR4 SUPPRESSES SELF-RENEWAL IN GLIOBLASTOMA
Authors: Justin Lathia, Alvaro Alvarado, Michael Vogelbaum, James Hale, Daniel Silver
Journal: Neuro-Oncology (2016)

Multiple cellular and molecular components within the glioblastoma microenvironment work to maintain a balance between immune dampening and inflammation, effectively preventing immune rejection of the tumor. Therefore, revealing the mechanisms that dampen immune signaling is critically important. Immune response initiation can be activated by ligands recognized by the toll-like family of receptors (TLRs). TLR activation limits proliferation in developing neural systems, yet these pathways are generally drivers of proliferation in many tumors including glioblastoma. This functional shift is surprising, considering the number of developmental programs activated in self-renewing cancer stem cells (CSCs). While mechanisms responsible for TLR-mediated tumor progression are largely unknown, TLR ligands are currently under investigation as adjuvants for immunotherapy approaches. Using CSCs from glioblastoma patient-derived xenografts, we find that proliferation of non-CSCs is attenuated by TLR ligands, whereas CSC proliferation is unaffected by ligand exposure. Profiling revealed that CSCs have reduced TLR4 compared to non-CSCs and that low TLR4 expression correlates with aggressive disease progression. Overexpression of TLR4 in CSCs reduced stem cell signaling and attenuated proliferation, self-renewal, and tumor growth. Mechanistically, we found that TLR4 signaling is directly connected to the stem cell transcriptional program by way of tank-binding kinase 1 (TBK1) and retinoblastoma binding protein 5 (RBBP5). Further, RBBP5 is necessary and sufficient for CSC self-renewal via epigenetic regulation of core self-renewal transcription factors. The activation of TBK1 downstream of TLR4 is responsible for RBBP5 suppression. Our findings reveal a unique pathway through which TLR4 can potently suppress the stem cell state, linking innate immune signaling responses to stem cell maintenance. These data suggest that strategies to activate the immune system may also negatively impact stem cell programs in tumor cells, indicating that approaches that alter the immune system also target the treatment-refractory CSC population.
Asthmatic subjects with allergy have elevated levels of IgE+ B cells in the airways
Authors: John-Paul Oliveria, Brittany M Salter, Stephanie Phan, Caitlin D Obminski, Caroline E Munoz, Steven G Smith, Tara Scime, Rick M Watson, Roma Sehmi, Gail M Gauvreau
Journal: Journal of Allergy and Clinical Immunology (2017)
Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study
Authors: D. Mahalingam, M.R. Patel, J.C. Sachdev, L.L. Hart, N. Halama, R.K. Ramanathan, J. Sarantopoulos, X. Liu, S. Yazji, D. Jäger, M. Yoon, G.Ç Manzur, D. Adib, R. Kerschbaumer, A. Tsimberidou
Journal: Annals of Oncology (2016)
Dalteparin vs. vitamin K antagonist (VKA) for the prevention of recurrent venous thromboembolism (VTE) in cancer patients with renal insufficiency: A patient level pharmacoeconomic analysis in three European countries
Authors: L. Shane, G. Dranitsaris, S. Woodruff, J.-P. Galanaud, G. Stemer, P. Debourdeau, B. Valtier, L. Burgers
Journal: Annals of Oncology (2016)
Reactivation of JC Virus in 171 Allografted Patients: Incidence and Clinical Significance
Authors: Irit Avivi, Talia Wittman, Noam Benyamini, Zipora Kra-Oz, Moran Szwrcwort, Ilana Oren, Jacob M Rowe, Israel Henig, Tsila Zuckerman, Netanel Horowitz
Journal: Blood (2012)
MEDU-13. CONVERGENCE OF BMI1 AND CHD7 ON ERK SIGNALLING IN MEDULLOBLASTOMA
Authors: Sara Badodi, Xinyu Zhang, Adrian Dubuc, Michael D. Taylor, Silvia Marino
Journal: Neuro-Oncology (2017)

Medulloblastoma is the most common malignant paediatric brain tumour and is associated with high morbidity and mortality. Medulloblastomas are currently classified into four distinct molecular subgroups (WNT, SHH, Group 3 and Group 4) with different prognosis and responses to therapy. The Polycomb group protein BMI1 sustains self-renewal of neural stem cells and promotes proliferation of neural progenitors during development and in adult tissue homeostasis. Upregulation of BMI1 has been described in a plethora of cancers, including medulloblastoma, and it correlates with clinical stage and poor prognosis. BMI1 is overexpressed across all medulloblastoma subgroups but it is highest in Group 4 where it sustains tumour growth. Insertional mutagenesis of the T2Onc2 transposon by Sleeping Beauty transposase in glutamatergic progenitors overexpressing BMI1 leads to medulloblastoma formation, while neither Bmi1 over-expression nor T2Onc2 transposition alone drives tumorigenesis. These medulloblastomas show frequent inactivating insertions in the chromatin remodelling factor Chd7 (Chromodomain helicase DNA binding factor 7), suggesting that upregulation of BMI1 together with CHD7 loss of function can cooperate to initiate MB tumorigenesis. A BMI1High;CHD7Low molecular signature is associated with poor prognosis in human medulloblastoma and single copy loss and inactivating mutations of CHD7 are found in medulloblastoma Group 4. Silencing of CHD7 in primary patient-derived Group 4 medulloblastoma cells results in increased proliferation and upregulation of markers characteristic of undifferentiated and highly proliferative progenitors. Notably, we demonstrate that the proliferative phenotype driven by CHD7 knockdown is dependent on BMI1. Finally we show a molecular convergence on ERK signalling mediated by CHD7 and dependent on BMI1 expression. These results shed further light on the role of BMI1 and CHD7 in medulloblastoma pathogenesis and raise the possibility that pharmacological targeting of BMI1 or ERK may be particularly indicated in a subgroup of medulloblastoma with low expression level of CHD7.
Everolimus / pazopanib (E/P) benefits genomically selected patients (pts) with metastatic urothelial carcinoma (mUC)
Authors: J. Bellmunt, S.A. Mullane, S. Jacobus, L. Polacek, D.Y. Takeda, L. Harshman, T. Choueiri, N. Wagle, E.M. Van Allen, P. Kantoff, J.E. Rosenberg
Journal: Annals of Oncology (2016)
HMGA2 As a Potential Molecular Target in MLL-AF4 Positive Infant Acute Lymphoblastic Leukemia
Authors: Minenori Eguchi-Ishimae, Mariko Eguchi, Zhouying Wu, Wen Ming, Hidehiko Iwabuki, Takeshi Inukai, Kanji Sugita, Eiichi Ishii
Journal: Blood (2014)
Switch maintenance therapy with racotumomab or nimotuzumab vs docetaxel for NSCLC patients
Authors: M. Hernandez, E. Neninger, R.A. Ortiz, K. Camacho, R.M. Amador, L. Bello, Y. Flores, S. Acosta, G. Pichs, M. Cala, M. Corella, Y. Jimenez, Y. Diaz, C.E. Viada, M. Robina, A. Valdes, I.C. Mendoza, P.P. Guerra, A. Macias, T. Crombet
Journal: Annals of Oncology (2016)
Using Social Media as a Research Recruitment Tool: Ethical Issues and Recommendations
Authors: Luke Gelinas, Robin Pierce, Sabune Winkler, I. Glenn Cohen, Holly Fernandez Lynch, Barbara E. Bierer
Journal: The American Journal of Bioethics (2017)

The use of social media as a recruitment tool for research with humans is increasing, and likely to continue to grow. Despite this, to date there has been no specific regulatory guidance and there has been little in the bioethics literature to guide investigators and institutional review boards (IRBs) faced with navigating the ethical issues such use raises. We begin to fill this gap by first defending a nonexceptionalist methodology for assessing social media recruitment; second, examining respect for privacy and investigator transparency as key norms governing social media recruitment; and, finally, analyzing three relatively novel aspects of social media recruitment: (i) the ethical significance of compliance with website "terms of use"; (ii) the ethics of recruiting from the online networks of research participants; and (iii) the ethical implications of online communication from and between participants. Two checklists aimed at guiding investigators and IRBs through the ethical issues are included as appendices.
GENT-08. HUMAN GLIOBLASTOMA ASTROCYTES RESEMBLE FETAL ASTROCYTE PRECURSOR CELLS AS REVEALED BY IMMUNOPANNING AND RNAseq
Authors: Ye Zhang, Steven Sloan, Ben Barres, Melanie Hayden Gephart
Journal: Neuro-Oncology (2016)

Genes and pathways active in glioblastoma astrocytes yet quiescent in mature astrocytes hold vast therapeutic potential. We hypothesized that glioblastoma astrocytes have reverted to a ‘precursor’ state, as defined by the expression of fetal astrocyte genes. We have developed an innovative method leveraging primary human tissue to study in culture the individual cell subtypes comprising normal brain and glioblastoma. Prior studies in the field have relied on bulk glioblastoma tissue in which more numerous non-tumor or bystander cells drown out the glioblastoma astrocyte gene signature. We applied novel immunopanning separation methods (HepaCAM) to isolate human astrocytes from fetal, adult, and glioblastoma specimens. Previous cell sorting techniques (e.g. FACS) kill the primary brain cells quickly, lead to reactive states, are contaminated with other cell types, or can only be done on fetal rodent cells. Human fetal, adult, and glioblastoma astrocytes then underwent RNA-seq and culture. We compared transcriptional similarities between glioblastoma and normal mature and fetal astrocytes, all using fresh, human tissue. Once isolated, we found our astrocytes were minimally reactive, highly pure, and could be maintained in primary cell culture with serum-free media. Unsupervised hierarchical clustering of gene expression profiles showed glioblastoma astrocytes grouped with human astrocyte precursor cells (fetal) compared to mature astrocytes. Genes that distinguished astrocyte precursor cells from mature human astrocytes were shared by glioblastoma astrocytes. The molecular profiles of astrocyte precursor cells were overwhelmingly immature and proliferative, in sharp distinction to the human mature resting astrocyte profiles. Human glioblastoma astrocytes have a similar gene expression profile to fetal astrocyte precursor cells. Application of the immunopanning technique will allow us to study in vitro the transcriptional profiles and phenotypes of brain and glioblastoma cellular subtypes, reliably recapitulating the human disease and suggesting therapeutic targets.
Retrospective observational study of Vinflunine (VFL) in patients (pts) with transitional cell carcinoma of the urothelial tract (TCCU): final results of a real world population study (MOVIE-GOIRC01/2014 trial)
Authors: R. Passalacqua, S. Lazzarelli, R. Montironi, S. Pignata, U. De Giorgi, A. Bernardo, G.L. Ceresoli, G. Delconte, M. Donini, E. Iezzi, E. Maiello, F. Nolè, S. Panni, B. Perrucci, E. Rondini, R. Sabbatini, M. Sequino, G. Tonini, P. Zucali, C. Caminiti
Journal: Annals of Oncology (2016)
RARE-40. BING-NEEL SYNDROME: DIAGNOSTIC &amp; THERAPEUTIC ISSUES
Authors: Lawrence Cher, Jim Griffiths
Journal: Neuro-Oncology (2016)

Bing-Neel Syndrome (BNS) is a rare syndrome, which was first described in 1936 prior to Waldenstrom’s description of his eponymous macroglobulinaemia. However, recent studies have better defined the condition and have shown it to have a reasonable prognosis. Treatment options however are not well defined. We present two cases that present both diagnostic and therapeutic issues in patients with known Waldenstrom’s Macroglobulinaemia (WM), also known as Lymphoplasmocytic Lymphoma. CASE 1: This patient had a past history of breast carcinoma and had long-standing WM found asymptomatically. She had completed chemotherapy for WM with CVP and developed numbness and gait difficulties initially attributed to vincristine. She was allergic to Rituximab. She had features of a myelopathy and MRI showed diffuse myelopathy with enhancement and oedema with leptomeningeal enhancement. ON CSF flow cytometry the WM clone noted previously was identified. She was treated with 9 cycles of high dose Methotrexate (8 gm/m2) and will be considered for Ibrutinib therapy. MRI changes were minimal but she had significant neurologic improvement and stabilisation. CASE 2: This elderly patient presented following a single drop attack and was found to have a meningeal lesion involving the falx anteriorly. It was unclear if this was related to her event. She had a long history of WM and systemic disease was under control with prior therapies. This was followed but continued to slowly increase in size, with infiltration into the surrounding parenchyma. Biopsy confirmed WM rather than meningioma. She was treated successfully with focal radiation therapy with a good response. These cases show that BNS needs to be considered and can have a varied presentation. Recent studies have shown the condition to the responsive to therapy although given it’s rarity there is no consensus. Newer therapies such as the BTK inhibitors may have a role as well.
Oral Quinolone Switch after 8 Days of Aminoside Is an Efficient and Safe Antibiotherapeutic Strategy for Febrile Neutropenia after Hematopoetic Stem Cell Transplantation.
Authors: Thomas Prebet, Karin Bilger, Fréderic Gomez, Catherine Sebban, Valérie Soumelis, Catherine Furhman, Mauricette Michallet, Pierre Biron
Journal: Blood (2005)
First Italian Multicentre Experience in using Ra-223 in patients with metastatic castration resistant prostate cancer (mCRPC)
Authors: A. Farnesi, S. Mazzarri, L. Galli, G. Boni, C. Cianci, E. Biasco, A. Sbrana, F. Monari, V. Dionisi, T. Graziani, S. Fanti, F. Massari, A. Ardizzoni, E. Borsatti, R. Bortolus, C. Gobitti, L. Fratino, D. Volterrani, S. Ricci, A. Falcone
Journal: Annals of Oncology (2016)